ergometrine | 16369-53-2

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 麦角林及其衍生物
• 英文名称: ergometrine
• 英文别名: 6-methyl-9,10-didehydro-ergoline-8β-carboxylic acid-(2-hydroxy-ethylamide)；6-Methyl-9,10-didehydro-ergolin-8β-carbonsaeure-(2-hydroxy-aethylamid)；9,10-didehydro-N-(2-hydroxyethyl)-6-methylergoline-8β-carboxamide；9,10-Didehydro-N-(2-hydroxyethyl)-6-methylergoline-8beta-carboxamide；(6aR,9R)-N-(2-hydroxyethyl)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
• CAS: 16369-53-2
• 化学式: C₁₈H₂₁N₃O₂
• 分子量: 311.384
• InChiKey: MASOQEHOSJDSMH-MLGOLLRUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  68.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氢氧化钾 作用下， 生成 ergometrine
  参考文献：
  名称：

  部分合成冯Typus des Ergobasins。（6. MitteilungüberMutterkornalkaloide）

  摘要：

  DOI：

  10.1002/hlca.19430260326

文献信息

• Process for the manufacture of lysergic acid
  申请人：Cvak Ladislav

  公开号：US20070135638A1

  公开（公告）日：2007-06-14

  Lysergic acid is formed in high yields and high quality by isomerizing paspalic acid in a phase separated mixture formed by paspalic acid and a concentrated aqueous metal hydroxide solution.

  利酸通过在巴斯帕利酸和浓缩水合金属氢氧化物溶液形成的相分离混合物中异构化巴斯帕利酸而高产高质地形成。
• [EN] METHODS AND COMPOSITIONS FOR THE TREATMENT OF A CHAGAS DISEASE<br/>[FR] MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT DE LA MALADIE DE CHAGAS
  申请人：BIOMED VALLEY DISCOVERIES

  公开号：WO2014186623A2

  公开（公告）日：2014-11-20

  The present invention provides, inter alia, methods for treating or ameliorating the effects of a Chagas disease. The methods include administering to a subject in need thereof an effective amount of a first active agent selected from the group consisting of a histamine-H1-receptor antagonist, a selective neutrophil elastase inhibitor, an ergot alkaloid derivative, an inhibitor of 3 β-hydroxysteroid dehydrogenase, a reversible acetylcholinesterase inhibitor, a protease inhibitor, an aldosterone antagonist, a naphthoquinone, and combinations thereof, and a second active agent, which is benznidazole. Also provided are compositions for treating or ameliorating the effects of a Chagas disease. The compositions include azelastine and benznidazole in amounts effective to treat or ameliorate the effect of a Chagas disease and a pharmaceutically acceptable carrier.